Cargando…

Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan

The prognostic role of modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with salivary duct carcinoma (SDC) remains unclear. We conducted a multi-institutional retrospective cohort study of 140 SDC patients. The survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawakita, Daisuke, Tada, Yuichiro, Imanishi, Yorihisa, Beppu, Shintaro, Tsukahara, Kiyoaki, Kano, Satoshi, Ozawa, Hiroyuki, Okami, Kenji, Sato, Yuichiro, Shimizu, Akira, Sato, Yukiko, Fushimi, Chihiro, Takase, Soichiro, Okada, Takuro, Sato, Hiroki, Otsuka, Kuninori, Watanabe, Yoshihiro, Sakai, Akihiro, Ebisumoto, Koji, Togashi, Takafumi, Ueki, Yushi, Ota, Hisayuki, Shimura, Tomotaka, Hanazawa, Toyoyuki, Murakami, Shingo, Nagao, Toshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352036/
https://www.ncbi.nlm.nih.gov/pubmed/27894101
http://dx.doi.org/10.18632/oncotarget.13565
_version_ 1782514866400002048
author Kawakita, Daisuke
Tada, Yuichiro
Imanishi, Yorihisa
Beppu, Shintaro
Tsukahara, Kiyoaki
Kano, Satoshi
Ozawa, Hiroyuki
Okami, Kenji
Sato, Yuichiro
Shimizu, Akira
Sato, Yukiko
Fushimi, Chihiro
Takase, Soichiro
Okada, Takuro
Sato, Hiroki
Otsuka, Kuninori
Watanabe, Yoshihiro
Sakai, Akihiro
Ebisumoto, Koji
Togashi, Takafumi
Ueki, Yushi
Ota, Hisayuki
Shimura, Tomotaka
Hanazawa, Toyoyuki
Murakami, Shingo
Nagao, Toshitaka
author_facet Kawakita, Daisuke
Tada, Yuichiro
Imanishi, Yorihisa
Beppu, Shintaro
Tsukahara, Kiyoaki
Kano, Satoshi
Ozawa, Hiroyuki
Okami, Kenji
Sato, Yuichiro
Shimizu, Akira
Sato, Yukiko
Fushimi, Chihiro
Takase, Soichiro
Okada, Takuro
Sato, Hiroki
Otsuka, Kuninori
Watanabe, Yoshihiro
Sakai, Akihiro
Ebisumoto, Koji
Togashi, Takafumi
Ueki, Yushi
Ota, Hisayuki
Shimura, Tomotaka
Hanazawa, Toyoyuki
Murakami, Shingo
Nagao, Toshitaka
author_sort Kawakita, Daisuke
collection PubMed
description The prognostic role of modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with salivary duct carcinoma (SDC) remains unclear. We conducted a multi-institutional retrospective cohort study of 140 SDC patients. The survival impact of these hematological markers was evaluated using multivariate proportional hazard models.High mGPS (≥1) was significantly associated with worse survival (3-year overall survival (OS): 16.7% vs 66.1%, p-value=0.003; 3-year progression-free survival (PFS): 0.0% vs 27.9%, p-value<0.001). Additionally, high C-reactive protein (CRP) (≥0.39 mg/dl) was significantly associated with worse survival (3-year OS: 32.1% vs 68.2%, p-value=0.001; 3-year PFS: 7.1% vs 31.1%, p-value<0.001). These associations were consistent with multivariate analysis adjusted for established prognostic factors. Although we also found significant association of high NLR (≥2.5) with OS (HR 1.80; 95% confidence interval, 1.05-3.08) in multivariate analysis, this association were inconsistent with the results of PFS. In addition, we found no significant associations of PLR with survival. In conclusion, we found that mGPS, CRP and NLR were identified as prognostic factors associated with survival in SDC patients.
format Online
Article
Text
id pubmed-5352036
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-53520362017-04-13 Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan Kawakita, Daisuke Tada, Yuichiro Imanishi, Yorihisa Beppu, Shintaro Tsukahara, Kiyoaki Kano, Satoshi Ozawa, Hiroyuki Okami, Kenji Sato, Yuichiro Shimizu, Akira Sato, Yukiko Fushimi, Chihiro Takase, Soichiro Okada, Takuro Sato, Hiroki Otsuka, Kuninori Watanabe, Yoshihiro Sakai, Akihiro Ebisumoto, Koji Togashi, Takafumi Ueki, Yushi Ota, Hisayuki Shimura, Tomotaka Hanazawa, Toyoyuki Murakami, Shingo Nagao, Toshitaka Oncotarget Research Paper The prognostic role of modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in patients with salivary duct carcinoma (SDC) remains unclear. We conducted a multi-institutional retrospective cohort study of 140 SDC patients. The survival impact of these hematological markers was evaluated using multivariate proportional hazard models.High mGPS (≥1) was significantly associated with worse survival (3-year overall survival (OS): 16.7% vs 66.1%, p-value=0.003; 3-year progression-free survival (PFS): 0.0% vs 27.9%, p-value<0.001). Additionally, high C-reactive protein (CRP) (≥0.39 mg/dl) was significantly associated with worse survival (3-year OS: 32.1% vs 68.2%, p-value=0.001; 3-year PFS: 7.1% vs 31.1%, p-value<0.001). These associations were consistent with multivariate analysis adjusted for established prognostic factors. Although we also found significant association of high NLR (≥2.5) with OS (HR 1.80; 95% confidence interval, 1.05-3.08) in multivariate analysis, this association were inconsistent with the results of PFS. In addition, we found no significant associations of PLR with survival. In conclusion, we found that mGPS, CRP and NLR were identified as prognostic factors associated with survival in SDC patients. Impact Journals LLC 2016-11-24 /pmc/articles/PMC5352036/ /pubmed/27894101 http://dx.doi.org/10.18632/oncotarget.13565 Text en Copyright: © 2017 Kawakita et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Kawakita, Daisuke
Tada, Yuichiro
Imanishi, Yorihisa
Beppu, Shintaro
Tsukahara, Kiyoaki
Kano, Satoshi
Ozawa, Hiroyuki
Okami, Kenji
Sato, Yuichiro
Shimizu, Akira
Sato, Yukiko
Fushimi, Chihiro
Takase, Soichiro
Okada, Takuro
Sato, Hiroki
Otsuka, Kuninori
Watanabe, Yoshihiro
Sakai, Akihiro
Ebisumoto, Koji
Togashi, Takafumi
Ueki, Yushi
Ota, Hisayuki
Shimura, Tomotaka
Hanazawa, Toyoyuki
Murakami, Shingo
Nagao, Toshitaka
Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan
title Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan
title_full Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan
title_fullStr Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan
title_full_unstemmed Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan
title_short Impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in Japan
title_sort impact of hematological inflammatory markers on clinical outcome in patients with salivary duct carcinoma: a multi-institutional study in japan
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352036/
https://www.ncbi.nlm.nih.gov/pubmed/27894101
http://dx.doi.org/10.18632/oncotarget.13565
work_keys_str_mv AT kawakitadaisuke impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT tadayuichiro impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT imanishiyorihisa impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT beppushintaro impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT tsukaharakiyoaki impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT kanosatoshi impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT ozawahiroyuki impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT okamikenji impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT satoyuichiro impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT shimizuakira impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT satoyukiko impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT fushimichihiro impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT takasesoichiro impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT okadatakuro impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT satohiroki impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT otsukakuninori impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT watanabeyoshihiro impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT sakaiakihiro impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT ebisumotokoji impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT togashitakafumi impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT uekiyushi impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT otahisayuki impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT shimuratomotaka impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT hanazawatoyoyuki impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT murakamishingo impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan
AT nagaotoshitaka impactofhematologicalinflammatorymarkersonclinicaloutcomeinpatientswithsalivaryductcarcinomaamultiinstitutionalstudyinjapan